Former CytoDyn Executives Guilty in Biotech Fraud, Facing 20 Years Each

In a major legal outcome, former CytoDyn executives, Nader Pourhassan and Kazem Kazempour, were convicted of fraud for their involvement in misleading investors regarding the company's investigational drug, leronlimab, which was intended for HIV and COVID-19 treatment[1][2]. Pourhassan, who served as CytoDyn's CEO, and Kazempour, leading Amarex Clinical Research, were found guilty of inflating the company’s stock value by falsely reporting regulatory progress with the FDA from 2018 to 2021[1]. Their fraudulent activities resulted in CytoDyn raising over $300 million from investors, while Pourhassan and Kazempour profited significantly[2]. Now awaiting sentencing, both executives face the possibility of up to 20 years in prison for each count of their convictions[1][2].